A single arm, open lable, II phase clinical study of Camrelizumab combined with Apatinib mesylate and Fluzoparib in the treatment of metastatic castration-resistant prostate cancer
Latest Information Update: 03 Dec 2020
At a glance
- Drugs Camrelizumab (Primary) ; Fuzuloparib (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 03 Dec 2020 New trial record